SynthesisReviews in endocrine & metabolic disorders2026
Metabolic profiling of human follicular fluid to unravel the pathways involved in polycystic ovary syndrome - a systematic review.
Synthesis in Reviews in endocrine & metabolic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovary syndrome (PCOS), an endocrine-metabolic disorder, affects women of reproductive age. Follicular fluid (FF) reflects the biochemical microenvironment surrounding the oocyte, providing valuable insight into molecular mechanisms associated with PCOS. Metabolomics enables comprehensive profiling of small-molecule metabolites allowing the identification of disease-specific metabolic signatures, dysregulated pathways, and potential diagnostic/therapeutic targets. This systematic review summarizes available evidence on the FF metabolomic profile of women with PCOS compared to normo-ovulatory controls, aiming to identify PCOS-specific metabolic signatures and dysregulated metabolic pathways. PubMed, Web of Science, and Scopus were searched up to September 2025. Eligible studies were conducted in humans, included at least one group of women with PCOS and a control group with normal ovarian function and normal-weight. Thirty-one studies were included. FF from women with PCOS exhibited consistent metabolomic signatures across analytical platforms and cohorts. The most robust differences involved extensive lipidome alterations, along with amino acid and energy metabolism disturbances. Steroidogenic profiles showed higher testosterone and androsterone sulfate levels, while progesterone, 17-hydroxyprogesterone, and pregnenolone were decreased, suggesting impaired steroidogenesis. Fatty acid alterations included increased saturated, monounsaturated, and polyunsaturated fatty acids. Phosphatidylethanolamine species, triglycerides, and prostaglandin E2 were elevated, whereas phosphatidylcholine and lysophosphatidic acid species were reduced. Among water-soluble metabolites, isoleucine, succinate, malate, glycerol, hypoxanthine, and uracil were increased, while threonine, glutamine, arginine, citrulline, and 4PY were decreased. FF metabolomics reveals a PCOS signature characterized by lipid, amino acid, and energy metabolism dysregulation, potentially contributing to follicular dysfunction. Future studies should consider PCOS phenotypic heterogeneity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.